SCNI
Scinai Immunotherapeutics Ltd.Company Information
- Company Name
- Scinai Immunotherapeutics Ltd.
- CIK
- CIK0001611747
- Category
- Non-accelerated filer
- Ticker: Exchange
- SCNI: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- SCNI
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- —
- Institutional shares owned
- —
- Shares outstanding
- —
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2023-05-15
- Price on filing date
- —
- 1-month reaction
- -26.15%
- 3-month reaction
- -24.51%
Balance Sheet
Values in millions ($)| Line item | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||
| Cash And Cash Equivalents At Carrying Value | 11 | 14 | ||||||
| Restricted Cash Current | 0 | 0 | ||||||
| Other Receivables Net Current | - | 0 | ||||||
| Prepaid Expense Current | 0 | - | ||||||
| Assets Current | 11 | 14 | ||||||
Non Current Assets | ||||||||
| Property Plant And Equipment Net | 11 | 11 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | ||||||
| Assets Noncurrent | 12 | 13 | ||||||
| Assets | 23 | 27 | ||||||
Liabilities Current | ||||||||
| Accounts Payable Trade Current | 1 | 1 | ||||||
| Short Term Borrowings | - | 0 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | - | 1 | ||||||
| Operating Lease Liability | 0 | - | ||||||
| Other Accounts Payable And Accrued Liabilities | 1 | - | ||||||
| Liabilities Current | 3 | 2 | ||||||
Non Current Liabilities | ||||||||
| Derivative Liabilities | 3 | 5 | ||||||
| Other Loans Payable Long Term | 22 | 20 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | ||||||
| Liabilities Noncurrent | 26 | 26 | ||||||
Stockholders Equity | ||||||||
| Additional Paid In Capital | 116 | 116 | ||||||
| Retained Earnings Accumulated Deficit | -119 | -116 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -2 | ||||||
| Stockholders Equity | -5 | -2 | ||||||
| Liabilities And Stockholders Equity | 23 | 27 | ||||||
| Common Stock Shares Authorized | 5 | 5 | ||||||
| Common Stock Shares Issued | 0 | 0 | ||||||
| Shares Outstanding | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialScinai Immunotherapeutics Ltd. (SCNI) — SEC Financial Statements & Analysis
Scinai Immunotherapeutics Ltd. (SCNI) is a biological products, (no diagnostic substances) company, incorporated in L3. Scinai Immunotherapeutics Ltd. trades on Nasdaq as: SCNI. Scinai Immunotherapeutics Ltd. (SCNI)'s most recent SEC filing is a Form 10-Q for the period ended 2023-03-31, filed with the SEC on 2023-05-15. Based on that filing, Scinai Immunotherapeutics Ltd. carries a market cap of $69.94M, a P/B ratio of -14.54x, and an enterprise value of $59.02M. On the balance sheet, it maintains a current ratio of 4.28x, a quick ratio of 4.24x, working capital of $8.47M, a debt-to-equity ratio of -5.84x, a debt ratio of 1.21, and net debt of $-10.93M. Figures sourced from SEC EDGAR.
- Market Cap
- $69.94M
- P/B TTM
- -14.54x
- Debt To Equity
- -5.84x
Data as of 2023-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Scinai Immunotherapeutics Ltd. in?
Scinai Immunotherapeutics Ltd. (SCNI) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does SCNI trade on?
Scinai Immunotherapeutics Ltd. (SCNI) trades on the Nasdaq.
Where is Scinai Immunotherapeutics Ltd. incorporated?
Scinai Immunotherapeutics Ltd. is incorporated in Israel.
When was Scinai Immunotherapeutics Ltd. (SCNI)'s most recent SEC filing?
Scinai Immunotherapeutics Ltd. (SCNI)'s most recent SEC filing is a Form 10-Q for the period ended 2023-03-31, filed with the SEC on 2023-05-15.
What is SCNI's market cap?
Scinai Immunotherapeutics Ltd. (SCNI) has a market capitalization of $69.94M as of 2023-03-31.